Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acceptability of sublingual piribedil on top of L-dopa and a dopamine agonist in advanced Parkinson's disease
2005-002010-38Phase 3Completed
- Sponsor
- Servier
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of piribedil in Parkinson's disease (PD), sponsored by Servier. Primary endpoint: Acceptability based on the occurrence of adverse events. Started Feb 2006; status: completed.
02
Drugs
piribedil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2005-002010-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002010-38.